Logo
x

Search

Subscribe Now

I-Mab

I-Mab’s TJ271 (enoblituzumab) + Keytruda (pembrolizumab) Receives NMPA’s IND Approval to Initiate P-II Clinical Trial for Solid Tumors

I-Mab’s TJ271 (enoblituzumab) + Keytruda (pembrolizumab) Receives NMPA’s IND Approval to Initiate P-II Clinical Trial for Solid Tu...

  • December 28, 2021
PharmaShots Weekly Snapshots (November 08, 12, 2021)

PharmaShots Weekly Snapshots (November 08, 12, 2021)

  • November 12, 2021
PharmaShots Weekly Snapshots (August 09, 13, 2021)

PharmaShots Weekly Snapshots (August 09, 13, 2021)

  • August 13, 2021
PharmaShots Weekly Snapshots (April 26 - 30, 2021)

PharmaShots Weekly Snapshots (April 26 - 30, 2021)

  • April 30, 2021
Insights+: COVID-19 Healthcare News Monthly Updates - January 2020

Insights+: COVID-19 Healthcare News Monthly Updates - January 2020

  • December 31, 2020
AbbVie to License I-Mab's Lemzoparlimab (TJC4) for ~$2B

AbbVie to License I-Mab's Lemzoparlimab (TJC4) for ~$2B

  • September 4, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.